(Q37406061)

20 August 2017

1 reference

title

Stemming resistance to HER-2 targeted therapy (English)

1 reference

20 August 2017

author

Martine Piccart-Gebhart

series ordinal

3

object named as

Martine J Piccart-Gebhart

0 references

Philippe L. Bedard

object named as

Philippe L Bedard

series ordinal

1

0 references

Fátima Cardoso

object named as

Fatima Cardoso

series ordinal

2

0 references

publication date

4 March 2009

1 reference

Journal of Mammary Gland Biology and Neoplasia

20 August 2017

published in

1 reference

20 August 2017

volume

14

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

55-66

1 reference

https://scigraph.springernature.com/pub.10.1007/s10911-009-9116-x

20 August 2017

exact match

0 references

cites work

Notch signaling regulates mammary stem cell function and luminal cell-fate commitment.

1 reference

https://api.crossref.org/works/10.1007%2FS10911-009-9116-X

Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-009-9116-X

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-009-9116-X

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-009-9116-X

An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-009-9116-X

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-009-9116-X

Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy

21 January 2018

1 reference

12 December 2020

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

12 December 2020

Steroid hormone receptor status of mouse mammary stem cells

1 reference

12 December 2020

Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer

1 reference

12 December 2020

Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells

1 reference

12 December 2020

Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis

1 reference

12 December 2020

Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone

1 reference

12 December 2020

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

Identification of tumor-initiating cells in a p53-null mouse model of breast cancer

1 reference

12 December 2020

Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer

1 reference

12 December 2020

NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer

1 reference

12 December 2020

Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

1 reference

12 December 2020

Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis

1 reference

12 December 2020

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

1 reference

12 December 2020

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

12 December 2020

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

12 December 2020

Molecular portraits of human breast tumours

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis

1 reference

12 December 2020

The CD44+/CD24- phenotype is enriched in basal-like breast tumors

1 reference

12 December 2020

High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates

1 reference

12 December 2020

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

1 reference

12 December 2020

let-7 regulates self renewal and tumorigenicity of breast cancer cells

1 reference

12 December 2020

CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis

1 reference

12 December 2020

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

1 reference

12 December 2020

Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.

1 reference

12 December 2020

Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer

1 reference

12 December 2020

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

12 December 2020

The epithelial-mesenchymal transition generates cells with properties of stem cells

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation

1 reference

12 December 2020

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

1 reference

12 December 2020

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

1 reference

12 December 2020

CD44 in cancer progression: adhesion, migration and growth regulation

1 reference

12 December 2020

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

12 December 2020

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

12 December 2020

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

1 reference

12 December 2020

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

1 reference

12 December 2020

The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).

1 reference

12 December 2020

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

1 reference

12 December 2020

BRCA1 regulates human mammary stem/progenitor cell fate

1 reference

12 December 2020

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer

1 reference

12 December 2020

PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells

1 reference

12 December 2020

Sensitization of breast cancer cells to radiation by trastuzumab

1 reference

12 December 2020

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

1 reference

12 December 2020

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

1 reference

12 December 2020

Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression

1 reference

12 December 2020

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance

1 reference

12 December 2020

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

12 December 2020

Molecular definition of breast tumor heterogeneity

1 reference

12 December 2020

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

1 reference

12 December 2020

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

1 reference

12 December 2020

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

12 December 2020

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

12 December 2020

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Insights from transgenic mouse models of ERBB2-induced breast cancer

1 reference

12 December 2020

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

12 December 2020

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

12 December 2020

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

1 reference

12 December 2020

Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.

1 reference

12 December 2020

Prospective identification of tumorigenic breast cancer cells

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

1 reference

12 December 2020

The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis

1 reference

12 December 2020

HER-2/neu diagnostics in breast cancer

1 reference

12 December 2020

HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.

1 reference

12 December 2020

10.1007/S10911-009-9116-X

Identifiers

DOI

1 reference

20 August 2017

1 reference